🇺🇸 FDA
Patent

US 12173306

Codon-optimized reduced-size ATP7A CDNA and uses for treatment of copper transport disorders

granted A61KA61K33/34A61K38/46

Quick answer

US patent 12173306 (Codon-optimized reduced-size ATP7A CDNA and uses for treatment of copper transport disorders) held by The United States of America as Represented by the Secretary, Dept. of Health and Human Services expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary, Dept. of Health and Human Services
Grant date
Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K33/34, A61K38/46, A61K48/005, A61P